• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

Lentivirus-mediated TCR Gene Transfer Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs offers lentivirus-mediated gene transfer services for the generation of TCR-modified T cells. Lentivirus can effectively integrate its constructed exogenous genes into the genome of various cell types including cytotoxic T lymphocytes (CTLs) and peripheral blood lymphocytes (PBLs), which makes itself an attractive tool for engineering T cells. Several researches have confirmed the safety of lentiviral vectors as they do not increase the mutation or tumor incidence. We provide various lentiviral vectors to meet every customer`s requirement.

Figure: A scheme of TCR and a lentiviral vector co-expressing α and β TCR chains.

T lymphocytes play crucial roles in immunity, there are various gene therapy strategies targeting T cells. And the efficient gene transfer into T cells facilitates the treatment of several genetic dysfunctions, inherited diseases and acquired diseases, etc. In recent years, this strategy has also been proven to be an alternative solution for many diseases such as hemophilia, adenosine deaminase deficiency (ADA) and chronic granulomatous disease (CGD). In order to achieve a long-term gene transfer, various tools and methods are developed and researched. Among which, lentiviral vectors, derived from HIV-1, have shown promise to tansduce various cell types including some resting cell types. Lentiviral vectors allow mitosis-independent nuclear import of the preintegration complex, which make them preferred gene packaging & delivery vectors for transduction of nonproliferating cells. There are mainly three types of strategies that are used to target lentiviral vectors-mediated to a given cell type or tissue. The first strategy is transductional targeting which is achieved by the modification of the vector surface. And the modification of vector surface can be performed by the incorporation of foreign envelope glycoproteins having a natural restricted tropism or the inclusion of specific ligands fused to the envelope proteins that will determine the affinity of the vector for a given target cell. The second strategy is transcriptional targeting that relies on the insertion of a tissue-specific promoter, or a fragment of this promoter, upstream of the therapeutic transgene. The third one is a novel method combining the microRNA (miRNA) post-transcriptional regulation with lentiviral technology.
With rich experience, Creative Biolabs will offer safe and well controlled expression systems used in TCR gene transfer.

The most popular strategies used for TCR gene transfer:

References:

1. Ines Dufait, et al. Gene therapy-tools and potential biochemistry. Chapter 13: Lentiviral vectors in immunotherapy. DOI: 10.5772/50717.
2. Els Verhoeyen, et al. Lentiviral Vector Gene Transfer into Human T Cells. Christopher Baum (ed.), Methods in Molecular Biology, Methods and Protocols, vol. 506.
3. Cecilia Frecha, et al. Strategies for Targeting Lentiviral Vectors. Current Gene Therapy, 2008, 8, 449-460.

To discuss your demands or to request a proposal, please contact us by .